AbbVie, with a market cap of over $300 billion, shows strong cash flow potential despite patent expirations, making it a valuable investment. The company reported strong 3Q financials, with adjusted ...

I rate ASO a buy due to gross margin expansion, store growth, adoption by higher-earners, supporting free cash flow growth, and maintaining capital returns through repurchases. ASO's valuation is ...